Pediatric Drugs

, Volume 11, Issue 3, pp 171–183

Pediatric Generalized Anxiety Disorder

Epidemiology, Diagnosis, and Management
  • Courtney Pierce Keeton
  • Amie C. Kolos
  • John T. Walkup
Therapy In Practice

DOI: 10.2165/00148581-200911030-00003

Cite this article as:
Keeton, C.P., Kolos, A.C. & Walkup, J.T. Pediatr-Drugs (2009) 11: 171. doi:10.2165/00148581-200911030-00003

Abstract

Pediatric generalized anxiety disorder (GAD) is characterized by excessive and uncontrollable worry about a variety of events and is accompanied by physical symptoms such as headaches, tension, restlessness, gastrointestinal distress, and heart palpitations. Symptoms impose marked distress and interfere with social, emotional, and educational functioning. GAD occurs in over 10% of children and adolescents, has an average age of onset of 8.5 years, and is more often reported in girls. Common co-occurring conditions include separation anxiety disorder and social phobia.

Assessment involves a multi-informant, multi-method approach involving the child, parents, and school teachers. A clinical interview should be conducted to assess for the three primary ways anxiety presents: behaviors, thoughts, and somatic symptoms. Several semi-structured diagnostic interviews are available, and the Anxiety Disorders Interview Schedule is increasingly used. Rating scales completed by the patient, caregivers, and teachers provide useful information for diagnosis and symptom monitoring. Several scales are available to assess patients for the Diagnostic and Statistical Manual of Mental Disorders (4th Edition) GAD diagnosis; however, instruments generally cannot distinguish children with GAD from children with similar anxiety disorders.

Both cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) have demonstrated efficacy for the treatment of pediatric anxiety disorders including GAD. Evidence suggests that the combination of CBT plus sertraline offers additional benefit compared with either treatment alone. With pharmacotherapy, systematic tracking of treatment-emergent adverse events such as headaches, stomach aches, behavioral activation, worsening symptoms, and emerging suicidal thoughts is important. Recommended starting doses are fluvoxamine 25mg/day, fluoxetine 10mg/day, and sertraline 25mg/day, though lower starting doses are possible. Dosing can be adjusted as often as weekly with the goal of achieving a high-quality response, while minimizing side effects. Long-term treatment with medication has not been well studied; however, to achieve optimal long-term outcome extended use of medication may be required. It is recommended to continue medication for approximately 1 year following remission in symptoms, and when discontinuing medication to choose a stress-free time of the year. If symptoms return, medication re-initiation should be considered seriously.

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Courtney Pierce Keeton
    • 1
  • Amie C. Kolos
    • 1
  • John T. Walkup
    • 1
  1. 1.Division of Child and Adolescent PsychiatryJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Division of Child and Adolescent PsychiatryJohns Hopkins Children’s CenterBaltimoreUSA